EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally Mature

Karen Fritchie, Baptiste Ameline, Vanghelita Andrei, Greg Charville, Jason L Hornick, David M Meredith, Ivy John, Michael Michal, Tamas Pancsa, Scott E Kilpatrick, John Reith, Zhen Wang und 14 weitere

Modern Pathology · 2025

DOI: 10.1016/j.modpat.2025.100790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Karen Fritchie und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address: fritchk@ccf.org. Hauptthemen laut MEDLINE: Chondroblastoma, Bone Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant chondroblastoma is a recently described variant of chondroblastoma showing a distinct age/site distribution and morphology along with the typical H3-3B p.K36M mutation. We sought to further compare conventional and malignant chondroblastoma. Malignant chondroblastomas were collected. H3-3 K36M immunohistochemistry, as well as DNA methylation and copy number profiling, were performed and compared with conventional chondroblastoma. Forty-one samples from 26 patients were identified (20 males, 6 females; age: 19-62 years; median: 39 years). Anatomical sites included rib (7), pelvis (4), acromion (4), scapula (4), spine (2), long bone (3), calcaneus (1), and talus (1). Imaging showed an expansile mass with variable cortical erosion and/or breakthrough. Most patients (n = 17) showed sheets of atypical ovoid cells deposited in a myxoid stroma. Osteoclast-like giant cells/matrix formation was scarce. Six patients had tumors with features of conventional chondroblastoma but significant cytologic atypia. Three tumors demonstrated a morphology indistinguishable from conventional chondroblastoma except for extensive permeation, and one of these cases showed a transition to high-grade sarcoma. The final case was composed only of high-grade pleomorphic sarcoma that harbored an H3F3A p.K36M mutation. When an adjacent host bone was present, permeative growth through the cortex and native trabeculae was noted. All samples tested positive for the H3-3 K36M-specific antibody (26 of 26). Methylome profiling of 28 specimens from 24 patients revealed that 26 of these specimens formed a distinct cluster on a uniform manifold approximation and projection dimension reduction plot separate from conventional chondroblastoma and high-grade osteosarcoma. Of 26 methylomes from which interpretable copy number profiles can be derived, 12 had no variations, whereas 14 had copy number changes. Of 22 patients, 11 experienced local recurrence, 8 patients developed metastasis, and 3 patients died of disease. Malignant chondroblastoma is a rare, clinically and epigentically distinct variant of chondroblastoma with a predilection for the flat bones of skeletally mature individuals and high rates of local recurrence and distant metastases. A subset transforms into high-grade pleomorphic sarcoma, either de novo or in subsequent recurrences. Malignant chondroblastoma with high-grade features and/or copy number variations appears to have a higher propensity for adverse events, including death from disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondroblastomaBone NeoplasmsEpigenesis, GeneticHumansMaleFemaleAdultYoung AdultMiddle AgedDNA MethylationBiomarkers, TumorMutationHistonesDNA Copy Number VariationsImmunohistochemistry

Stichwörter der Autor:innen

bonechondroblastomamalignant chondroblastomamethylationorthopedic

Substanzen

Biomarkers, TumorHistones

Autor:innen und Institutionen

  • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address: fritchk@ccf.org.
  • Bone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Department of Anatomic Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Bioptical Laboratory, Ltd, Pilsen, Czech Republic; Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Zitieren

APA

Fritchie, K., Ameline, B., Andrei, V., Charville, G., Hornick, J. L., Meredith, D. M., John, I., Michal, M., Pancsa, T., Kilpatrick, S. E., Reith, J., Wang, Z., Horvai, A., Gross, J., Sumathi, V., Davis, J. L., Purgina, B., Raymond, D. P., Ilaslan, H., …, & Baumhoer, D. (2025). Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally Mature. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100790

Vancouver

Fritchie K, Ameline B, Andrei V, Charville G, Hornick JL, Meredith DM, et al. Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally Mature. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100790

BibTeX
@article{Fritchie2025,
  author = {Fritchie, Karen and Ameline, Baptiste and Andrei, Vanghelita and Charville, Greg and Hornick, Jason L and Meredith, David M and John, Ivy and Michal, Michael and Pancsa, Tamas and Kilpatrick, Scott E and Reith, John and Wang, Zhen and Horvai, Andrew and Gross, John and Sumathi, Vaiyapuri and Davis, Jessica L and Purgina, Bibianna and Raymond, Daniel P and Ilaslan, Hakan and Chrisinger, John and Din, Nasir Ud and Hung, Yin P and Nielsen, Gunnlaugur P and Mogler, Carolin and Papke, David J and Baumhoer, Daniel},
  title = {Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally Mature},
  journal = {Modern Pathology},
  year = {2025},
  doi = {10.1016/j.modpat.2025.100790}
}
Kostenlos starten →